Aspen Pharmacare sees weight-loss drugs driving earnings
Aspen sells Mounjaro, the weight-loss drug made by US manufacturer Eli Lilly, in South Africa.
Aspen Pharmacare, a South African drugmaker, anticipates a 17% increase in earnings next year, driven by the rollout of its weight-loss drugs. The company sells Mounjaro, a weight-loss drug manufactured by Eli Lilly, in South Africa and plans to introduce its own generic version, targeting local markets as well as South America and the Middle East.
With demand from Africa currently representing only a small fraction of the global weight-loss drug market projected to reach $100 billion by 2030, obesity cases are on the rise, projected to double by 2050, and causing significant public health concerns. South Africa is emerging as the primary battleground in the continent between leading providers of weight-loss drugs, with Eli Lilly's Mounjaro competing against Ozempic, manufactured by Danish company Novo Nordisk.
Brief written by urgent.news from Semafor's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
